PE

Peptron, Inc.

A biotech firm developing sustained-release peptide drugs using proprietary technology.

087010 | KO

Overview

Corporate Details

ISIN(s):
KR7087010005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로1628번길 37-24, 대전광역시

Description

Peptron, Inc. is a biotechnology company specializing in peptide engineering and the development of sustained-release (SR) medications. The company's core focus is its proprietary SmartDepot platform technology, which enables the long-acting formulation of peptide-based drugs to treat chronic and life-threatening disorders. A key area of development is in neurodegenerative diseases, with a notable pipeline candidate being a sustained-release formulation of exenatide, based on patents exclusively licensed from the NIH. Peptron operates its own GMP-compliant manufacturing facility to produce its SR formulations, supporting its progression from pre-clinical research to commercial-stage development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-11-10 00:00
단일판매ㆍ공급계약체결
Korean 10.5 KB
2021-08-13 00:00
[기재정정]사업보고서 (2020.12)
Korean 1.0 MB
2021-08-13 00:00
반기보고서 (2021.06)
Korean 810.6 KB
2021-08-13 00:00
[기재정정]반기보고서 (2021.06)
Korean 812.9 KB
2021-08-13 00:00
[기재정정]반기보고서 (2021.06)
Korean 812.9 KB
2021-08-04 00:00
주식등의대량보유상황보고서(약식)
Korean 62.5 KB
2021-08-02 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.5 KB
2021-07-20 00:00
주식등의대량보유상황보고서(일반)
Korean 97.8 KB
2021-07-20 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 99.6 KB
2021-05-20 00:00
주식등의대량보유상황보고서(일반)
Korean 95.9 KB
2021-05-17 00:00
분기보고서 (2021.03)
Korean 738.0 KB
2021-04-16 00:00
기업설명회(IR)개최
Korean 7.4 KB
2021-04-06 00:00
주식등의대량보유상황보고서(일반)
Korean 92.8 KB
2021-03-31 00:00
투자판단관련주요경영사항(표적항암 항체치료제 후보물질(PAb001-ADC) 기술이전 계약 체결)
Korean 10.8 KB
2021-03-30 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.4 KB

Automate Your Workflow. Get a real-time feed of all Peptron, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Peptron, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Peptron, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.